JP7196157B2 - Ｃｎｓ状態の治療 - Google Patents

Ｃｎｓ状態の治療 Download PDF

Info

Publication number
JP7196157B2
JP7196157B2 JP2020511399A JP2020511399A JP7196157B2 JP 7196157 B2 JP7196157 B2 JP 7196157B2 JP 2020511399 A JP2020511399 A JP 2020511399A JP 2020511399 A JP2020511399 A JP 2020511399A JP 7196157 B2 JP7196157 B2 JP 7196157B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
syndrome
benzyl
methanone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020511399A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020532508A (ja
JP2020532508A5 (https=
Inventor
俊哉 西
伸一 近藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of JP2020532508A publication Critical patent/JP2020532508A/ja
Publication of JP2020532508A5 publication Critical patent/JP2020532508A5/ja
Priority to JP2022199076A priority Critical patent/JP7469445B2/ja
Application granted granted Critical
Publication of JP7196157B2 publication Critical patent/JP7196157B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
JP2020511399A 2017-08-31 2018-08-30 Ｃｎｓ状態の治療 Active JP7196157B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022199076A JP7469445B2 (ja) 2017-08-31 2022-12-14 Ｃｎｓ状態の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553070P 2017-08-31 2017-08-31
US62/553,070 2017-08-31
PCT/JP2018/032949 WO2019045121A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CNS DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022199076A Division JP7469445B2 (ja) 2017-08-31 2022-12-14 Ｃｎｓ状態の治療

Publications (3)

Publication Number Publication Date
JP2020532508A JP2020532508A (ja) 2020-11-12
JP2020532508A5 JP2020532508A5 (https=) 2021-09-30
JP7196157B2 true JP7196157B2 (ja) 2022-12-26

Family

ID=63722720

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020511399A Active JP7196157B2 (ja) 2017-08-31 2018-08-30 Ｃｎｓ状態の治療
JP2022199076A Active JP7469445B2 (ja) 2017-08-31 2022-12-14 Ｃｎｓ状態の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022199076A Active JP7469445B2 (ja) 2017-08-31 2022-12-14 Ｃｎｓ状態の治療

Country Status (8)

Country Link
US (4) US11285139B2 (https=)
EP (1) EP3675852A1 (https=)
JP (2) JP7196157B2 (https=)
KR (1) KR102680786B1 (https=)
CN (2) CN116370475A (https=)
CA (1) CA3073925A1 (https=)
MX (1) MX2020001732A (https=)
WO (1) WO2019045121A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119192266A (zh) 2011-10-14 2024-12-27 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
ES2807264T3 (es) 2013-04-17 2021-02-22 Sage Therapeutics Inc Esteroides neuroactivos 19-nor para métodos de tratamiento
WO2014169831A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
WO2015010054A2 (en) 2013-07-19 2015-01-22 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
ES2848823T3 (es) 2013-08-23 2021-08-12 Sage Therapeutics Inc Esteroides neuroactivos, composiciones y usos de los mismos
WO2015195962A1 (en) 2014-06-18 2015-12-23 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
ME03809B (me) 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016123056A1 (en) 2015-01-26 2016-08-04 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP4155314A1 (en) 2015-02-20 2023-03-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MA45599A (fr) 2016-07-11 2019-05-15 Sage Therapeutics Inc Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation
US20190233465A1 (en) 2016-07-11 2019-08-01 Sage Therapeutics, Inc. C7, c12, and c16 substituted neuroactive steroids and their methods of use
TWI904593B (zh) 2016-08-23 2025-11-11 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
PT3711758T (pt) 2017-11-14 2024-04-22 Sk Biopharmaceuticals Co Ltd Utilização de composto de carbamato para prevenir, aliviar ou tratar crise de ausência ou epilepsia que apresenta crise de ausência
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CR20240234A (es) 2019-05-31 2024-07-09 Sage Therapeutics Inc ESTEROIDES NEUROACTIVOS Y COMPOSICIONES DE ESTOS (Divisional 2021-629)
JP2023504177A (ja) * 2019-12-02 2023-02-01 エフ．ホフマン－ラ ロシュ アーゲー アルキニル－（ヘテロアリール）－カルボキサミドｈｃｎ１阻害剤
GB2597285A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20240197704A1 (en) * 2021-04-09 2024-06-20 Johns Hopkins University Treatment methods and compositions comprising perampanel
CN115487144A (zh) * 2021-06-18 2022-12-20 北京万全德众医药生物技术有限公司 一种卢非酰胺的口服液制备方法
WO2023175591A1 (en) * 2022-03-18 2023-09-21 Takeda Pharmaceutical Company Limited Methods of treating neurological diseases
WO2024100531A1 (en) * 2022-11-07 2024-05-16 Takeda Pharmaceutical Company Limited Method of treating seizure disorders
WO2025126159A1 (en) * 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user
WO2025257799A1 (en) * 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Methods of treating dravet syndrome
CN121550436A (zh) * 2026-01-23 2026-02-24 四川大学华西医院 新靶点在结节性硬化症相关癫痫中的应用、组合物及联合用药方式

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014092100A1 (ja) 2012-12-11 2014-06-19 武田薬品工業株式会社 複素環化合物
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
JP2014528904A (ja) 2011-10-07 2014-10-30 武田薬品工業株式会社 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6807322B2 (ja) 2015-10-16 2021-01-06 武田薬品工業株式会社 複素環化合物の製造方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014528904A (ja) 2011-10-07 2014-10-30 武田薬品工業株式会社 神経変性疾患の治療に有用な１−アリールカルボニル−４−オキシ−ピペリジン化合物
WO2014092100A1 (ja) 2012-12-11 2014-06-19 武田薬品工業株式会社 複素環化合物
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Study of TAK-935 as an Adjunctive Therapy in Participants With developmental and/or Epileptic Encephalopathies，Clinical Trials.gov archive，2017年08月28日，NCT03166215
Takeda，Takeda and Ovid Therapeutics Announce Innovative Clinical Development and Commercialization Collaboration for TAK-935 in Rare Pediatric Epilepsies，2017年01月18日，https://www.takeda.com/newsroom/newsreleases/2017/Takeda-and-Ovid-Therapeutics-Announce-Innovative-Clinical-Development-and-Commercialization/

Also Published As

Publication number Publication date
JP2020532508A (ja) 2020-11-12
CN111065394B (zh) 2023-03-31
EP3675852A1 (en) 2020-07-08
JP7469445B2 (ja) 2024-04-16
JP2023027267A (ja) 2023-03-01
CN116370475A (zh) 2023-07-04
US20220168294A1 (en) 2022-06-02
CA3073925A1 (en) 2019-03-07
US20250281477A1 (en) 2025-09-11
US20230087903A1 (en) 2023-03-23
US11285139B2 (en) 2022-03-29
CN111065394A (zh) 2020-04-24
MX2020001732A (es) 2020-03-20
WO2019045121A1 (en) 2019-03-07
US20200306238A1 (en) 2020-10-01
KR102680786B1 (ko) 2024-07-02
KR20200046022A (ko) 2020-05-06

Similar Documents

Publication Publication Date Title
JP7196157B2 (ja) Ｃｎｓ状態の治療
US20240245631A1 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
US12465583B2 (en) Methods of treatment using an mTORC1 modulator
TW202142229A (zh) 治療雷葛氏症候群之病患的方法
EP3687518A1 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
TW202033197A (zh) 用於預防偏頭痛之拉米迪坦(lasmiditan)長期夜間投藥
WO2019067413A1 (en) USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
CN110214146B (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
CA3266630A1 (en) Combination treatment of scyllo-inositol and vitamin d and/or other vitamins or active ingredients to treat cognitive disorders
JP2023526634A (ja) 高アンモニア血症を治療するためのオルニチンフェニルアセテートの使用
JP2015505314A5 (https=)
Wang et al. Efficacy and tolerability of perampanel as add‐on therapy in Dravet syndrome: A prospective real‐world study
US8222278B2 (en) Treatment of attention-deficit/hyperactivity disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210818

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221013

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221115

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221214

R150 Certificate of patent or registration of utility model

Ref document number: 7196157

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150